Shane Armstrong

Theravance Biopharma US, Inc.

Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients' and caregivers' lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media.